{"organizations": [], "uuid": "0a235a5f89c22d2fd0ed9bf9754c862afe32e1a8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180409.html", "section_title": "Archive News &amp; Video for Monday, 09 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-oncology-venture-exercises-option/brief-oncology-venture-exercises-option-to-in-license-dovitinib-a-phase-3-multi-tyrosine-kinase-inhibitor-idUSFWN1RM074", "country": "US", "domain_rank": 408, "title": "BRIEF-Oncology Venture Exercises Option To In License Dovitinib A Phase 3 Multi Tyrosine Kinase Inhibitor", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.465, "site_type": "news", "published": "2018-04-09T17:29:00.000+03:00", "replies_count": 0, "uuid": "0a235a5f89c22d2fd0ed9bf9754c862afe32e1a8"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-oncology-venture-exercises-option/brief-oncology-venture-exercises-option-to-in-license-dovitinib-a-phase-3-multi-tyrosine-kinase-inhibitor-idUSFWN1RM074", "ord_in_thread": 0, "title": "BRIEF-Oncology Venture Exercises Option To In License Dovitinib A Phase 3 Multi Tyrosine Kinase Inhibitor", "locations": [], "entities": {"persons": [], "locations": [{"name": "sweden", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "novartis", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 9 (Reuters) - Oncology Venture Sweden AB:\n* ONCOLOGY VENTURE EXERCISES OPTION TO IN LICENSE DOVITINIB A PHASE 3 MULTI TYROSINE KINASE INHIBITOR\n* ENTERED INTO AN AGREEMENT WITH NOVARTIS FOR EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE DOVITINIB\n* NOVARTIS WILL RECEIVE AN UPFRONT PAYMENT, DEVELOPMENT MILESTONES, AND ROYALTIES ON SALES.\n* NOVARTIS WILL BE ISSUED A CONVERTIBLE DEBT-TO-EQUITY NOTE IN A SPINOUT COMPANY THAT OV HAS CREATED\n* WILL FURTHER REFINE DOVITINIB DRPÂ® BIOMARKER Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-09T17:29:00.000+03:00", "crawled": "2018-04-10T12:59:34.018+03:00", "highlightTitle": ""}